Metabolic syndrome during female midlife: what are the risks?
- PMID: 30712398
- DOI: 10.1080/13697137.2018.1561666
Metabolic syndrome during female midlife: what are the risks?
Abstract
The metabolic syndrome (METS) is an entity diagnosed by three or more of the following factors: abdominal obesity, low high-density lipoprotein cholesterol, and high serum triglycerides, fasting glucose, and/or blood pressure levels. Abdominal obesity is the most prevalent component of the syndrome that favors insulin resistance and a proinflammatory and prothrombotic status, and the risk of developing diabetes, hypertension, and other chronic conditions. During the menopausal transition, women tend to gain weight and this has been related to an increase in the prevalence of the METS. Rates have also been linked to hormonal status (perimenopausal vs. postmenopausal), changes in lifestyle, and endocrine adjustments. Abnormal cytokine secretion subsequently produces endothelial dysfunction, which will consequently increase cardiovascular risk and related morbidity and mortality. This document will review the various risks that arise as a consequence of the METS during female midlife.
Keywords: Metabolic syndrome; inflammation; insulin resistance; menopause; midlife; obesity; risks.
Comment in
-
Women and diabetes: disparity in treatment.Climacteric. 2019 Aug;22(4):424. doi: 10.1080/13697137.2019.1588243. Epub 2019 Mar 25. Climacteric. 2019. PMID: 30907684 No abstract available.
-
The metabolic syndrome and diabetes are not synonymous.Climacteric. 2019 Aug;22(4):425. doi: 10.1080/13697137.2019.1605758. Epub 2019 Apr 29. Climacteric. 2019. PMID: 31030574 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical